Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 35, 2021 - Issue 24
227
Views
7
CrossRef citations to date
0
Altmetric
Short Communications

Cytotoxic effect of pure compounds from Piper rivinoides Kunth against oral squamous cell carcinoma

, , , , , , , & ORCID Icon show all
Pages 6163-6167 | Received 23 Jun 2020, Accepted 13 Sep 2020, Published online: 14 Oct 2020
 

Abstract

The oral squamous cell carcinoma (OSCC) is the eighth more common cancer in men. The development of new and more efficient drugs is needed. Plants of the genus Piper are popularly used in the treatment of many diseases. This study evaluated the antitumor effect of extract, fraction and isolated compounds from leaves of P. rivinoides in oral cancer. The isolated compounds (conocarpan, eupomatenoid-5 and eupomatenoid-6) were effective in inducing cell death in OSCC cell lines (SCC4, SCC9 and SCC25) compared to the standard chemotherapeutic agent carboplatin, and this effect was time-dependent. Conocarpan was more selective and stable than eupomatenoid-5 and eupomatenoid-6, resembling the stability of carboplatin. There was a significant presence of pyknotic nuclei and active caspase-3 expression under conocarpan treatment, suggesting cell death through apoptosis. In conclusion, conocarpan was the most effective compound against OSCC cells and might be considered for future cancer studies.

Acknowledgements

The authors would like to acknowledge the agencies that fund our research: CNPq (PROEP 407845/2017-8), CAPES (Finance Code 001) and FAPERJ (E-26/202.787/2019 – JCNE).

Disclosure statement

The authors declare no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.